ABBOTT PARK, Ill., Jan. 10, 2017
/PRNewswire/ -- Abbott (NYSE: ABT) announced today its
Alinity™ s System for blood and plasma screening received CE Mark
and is now available in Europe and
other countries that recognize CE Mark. The new testing solution is
designed to screen blood and plasma faster and more efficiently
within a smaller footprint than Abbott's current systems. In a
testing specialty that can require extensive hands-on time, the
additional automation and flexibility of the Alinity s System helps
blood and plasma centers improve productivity and maintain the
highest levels of accuracy, without expanding the instrument
footprint.
"The Alinity s System is a significant leap forward when it
comes to speed, automation and efficiency for blood and plasma
screening," said Louis Morrone,
divisional vice president and general manager for Abbott's
Transfusion Medicine business. "These elements are important to
blood and plasma services of all sizes, supporting Abbott's overall
mission to help people live longer, healthier lives by keeping the
global blood and plasma supply safe."
The Alinity s System will help transform the blood and plasma
screening process in terms of speed, capacity and "walk-away" time
(i.e., when lab professionals are free to manage other
responsibilities while the instrument processes samples without
direct interaction) as a result of a number of new
features1:
- Expands capacity to run up to 600 tests per hour, at least
twice as much as competitive standalone instruments.
- Improves centers' ability to track all activities and actions
associated with the testing and processing of each donation in
accordance with relevant legislation and requirements.
- Increases walk-away time to a minimum of three hours.
- Gives laboratory professionals the ability to continuously load
and unload samples and supplies without pausing or stopping the
system.
- Features an intuitive software interface, menu design and
sample loading layout, shared with other Alinity instruments,
making it easy for lab technicians to learn and use.
"When Abbott developed the Alinity s system, we considered the
challenges that blood and plasma centers face today as well as in
the future, such as adequate space, easier training, and more time
for lab professionals to work away from the instrument," said Daman
Kowalski, divisional vice president of new product development in
Diagnostics at Abbott. "In addressing these challenges, the Alinity
s System has the potential to transform how quickly and accurately
these centers can screen blood and plasma, which means we can
deliver life-saving blood components to the people who need it the
most."
About Alinity
Abbott's Alinity family of harmonized
solutions is unprecedented in the diagnostics industry, working
together to address the challenges of using multiple diagnostics
platforms and simplify diagnostic testing. Alinity systems are
designed to be more efficient – running more tests in less space,
generating test results faster and minimizing human errors – while
continuing to provide quality results.
The Alinity portfolio includes clinical chemistry, immunoassay,
blood and plasma screening, point of care, hematology and molecular
diagnostics, along with Abbott's AlinIQ—a first-of-its-kind,
holistic suite of professional services that combines expertise
with process analysis and informatics. Alinity is helping labs and
hospital systems solve some of their most pressing challenges to
deliver better patient care with fewer resources. More information
is available at abbott.com/alinity.
About Abbott
At Abbott, we're committed to helping you
live your best possible life through the power of health. For more
than 125 years, we've brought new products and technologies to the
world -- in nutrition, diagnostics, medical devices and branded
generic pharmaceuticals -- that create more possibilities for more
people at all stages of life. Today, 74,000 of us are working to
help people live not just longer, but better, in the more than 150
countries we serve.
Connect with us at www.abbott.com, on Facebook at
www.facebook.com/Abbott and on Twitter @AbbottNews and
@AbbottGlobal.
1 Abbott "Alinity s" System Operations Manual.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/abbott-announces-ce-mark-for-its-alinity-s-blood-and-plasma-screening-system-300388282.html
SOURCE Abbott